Technical Analysis for CLBS - Caladrius Biosciences, Inc.

Grade Last Price % Change Price Change
grade A 5.0 0.81% 0.04
CLBS closed up 0.81 percent on Friday, January 18, 2019, on 42 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.
4 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical CLBS trend table...

Date Alert Name Type % Chg
Jan 18 Narrow Range Bar Range Contraction 0.00%
Jan 18 NR7 Range Contraction 0.00%
Jan 18 Wide Bands Range Expansion 0.00%
Jan 18 Overbought Stochastic Strength 0.00%
Jan 17 Narrow Range Bar Range Contraction 0.81%
Jan 17 Wide Bands Range Expansion 0.81%
Jan 17 Overbought Stochastic Strength 0.81%
Jan 16 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.60%
Jan 16 Narrow Range Bar Range Contraction 0.60%
Jan 16 Inside Day Range Contraction 0.60%

Older signals for CLBS ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Get Started for Free!
Configure default chart indicators
Basic chart:

Profile
Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, develops cell based therapeutics in the United States. It is developing NBS20, a targeted cancer immunotherapy product that is in Phase III clinical trials for the treatment of metastatic melanoma; NBS10, a ischemic repair product that is in Phase II clinical trial to preserve heart muscle function following an acute myocardial infarction; and NBS03D, an immune modulation product that is in Phase II clinical trials for the treatment of type 1 diabetes. The company, through its subsidiary, Progenitor Cell Therapy, offers process development and clinical manufacturing services. It is also involved in oncology, cord blood, and adult stem cell processing and banking activities; and the provision of clinical services. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was founded in 1980 and is headquartered in New York, New York.
Is CLBS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Jan 7 Caladrius Biosciences to Participate in Upcoming January Conferences
Jan 2 Small med firms see increased buying
Dec 7 Small healthcare stocks shrug off broad market selling
Nov 15 Recent Analysis Shows Escalade, Caladrius Biosciences, LightInTheBox Holding Co., Vishay Intertechnology, Ceridian HCM Holding, and Avista Market Influences — Renewed Outlook, Key Drivers of Growth
Nov 13 70 Biggest Movers From Yesterday
Nov 12 Caladrius Biosciences, Inc. 2018 Q3 - Results - Earnings Call Slides
Nov 12 Healthcare and Tech tops midday movers
Nov 12 ReShape Lifesciences leads healthcare gainers; Infinity Pharmaceuticals and Achaogen among losers
Nov 9 Caladrius Biosciences to Participate in the Inv€$tival Showcase in Partnership with Jefferies and the Jefferies 2018 London Healthcare Conference
Nov 9 Caladrius Biosciences, Inc. (CLBS) CEO David Mazzo on Q3 2018 Earnings Conference Call Transcript
See more CLBS news...
Indicators
Indicator Value
52 Week High 11.65
52 Week Low 3.05
Average Volume 24,366
200-Day Moving Average 4.9129
50-Day Moving Average 4.5784
20-Day Moving Average 4.382
10-Day Moving Average 4.87
Average True Range 0.3603
ADX 24.95
+DI 22.1775
-DI 12.5017
Chandelier Exit (Long, 3 ATRs ) 4.0091
Chandelier Exit (Short, 3 ATRs ) 4.1309
Upper Bollinger Band 5.484
Lower Bollinger Band 3.28
Percent B (%b) 0.78
BandWidth 50.296668
MACD Line 0.1594
MACD Signal Line 0.0672
MACD Histogram 0.0922
Fundamentals Value
Market Cap 47.13 Million
Num Shares 9.43 Million
EPS -11.27
Price-to-Earnings (P/E) Ratio -0.44
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio -0.03
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.15
Resistance 3 (R3) 5.16 5.13 5.13
Resistance 2 (R2) 5.13 5.09 5.12 5.12
Resistance 1 (R1) 5.06 5.06 5.05 5.05 5.11
Pivot Point 5.03 5.03 5.02 5.02 5.03
Support 1 (S1) 4.96 4.99 4.95 4.95 4.89
Support 2 (S2) 4.93 4.96 4.92 4.88
Support 3 (S3) 4.86 4.93 4.88
Support 4 (S4) 4.85